Chimerix Management

Management criteria checks 2/4

Chimerix's CEO is Mike Andriole, appointed in Aug 2023, has a tenure of less than a year. total yearly compensation is $1.67M, comprised of 27.2% salary and 72.8% bonuses, including company stock and options. directly owns 0.35% of the company’s shares, worth $314.07K. The average tenure of the management team and the board of directors is 1.2 years and 6 years respectively.

Key information

Mike Andriole

Chief executive officer

US$1.7m

Total compensation

CEO salary percentage27.2%
CEO tenureless than a year
CEO ownership0.4%
Management average tenure1.2yrs
Board average tenure6yrs

Recent management updates

Recent updates

Chimerix: Advancement For Rare Brain Cancer Drug Targeting Specific Mutation

Aug 23

Here's Why We're Watching Chimerix's (NASDAQ:CMRX) Cash Burn Situation

Jul 20
Here's Why We're Watching Chimerix's (NASDAQ:CMRX) Cash Burn Situation

Chimerix: Down But Not Out

Jun 06

Chimerix: Searching For Clarity

Jan 05

Does Chimerix (NASDAQ:CMRX) Have A Healthy Balance Sheet?

Dec 24
Does Chimerix (NASDAQ:CMRX) Have A Healthy Balance Sheet?

Is Chimerix (NASDAQ:CMRX) A Risky Investment?

Sep 16
Is Chimerix (NASDAQ:CMRX) A Risky Investment?

Does Chimerix (NASDAQ:CMRX) Have A Healthy Balance Sheet?

Jun 08
Does Chimerix (NASDAQ:CMRX) Have A Healthy Balance Sheet?

Chimerix gets FDA approval for TEMBEXA for the treatment of smallpox

Jun 04

Chimerix, Inc. (NASDAQ:CMRX): Are Analysts Optimistic?

May 13
Chimerix, Inc. (NASDAQ:CMRX): Are Analysts Optimistic?

Chimerix Investor Presentation - Slideshow

May 08

Chimerix expands oncology program with acquisition of Oncoceutics, shares up 10%

Jan 08

Who Has Been Buying Chimerix, Inc. (NASDAQ:CMRX) Shares?

Jan 01
Who Has Been Buying Chimerix, Inc. (NASDAQ:CMRX) Shares?

Chimerix rises 9.1% premarket after FDA accepts NDA for smallpox countermeasure

Dec 07

Chimerix (NASDAQ:CMRX) Is In A Good Position To Deliver On Growth Plans

Dec 05
Chimerix (NASDAQ:CMRX) Is In A Good Position To Deliver On Growth Plans

Chimerix, Inc. 2020 Q3 - Results - Earnings Call Presentation

Nov 08

Chimerix EPS misses by $0.01, beats on revenue

Nov 05

CEO Compensation Analysis

How has Mike Andriole's remuneration changed compared to Chimerix's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023n/an/a

-US$82m

Sep 30 2023n/an/a

-US$85m

Jun 30 2023n/an/a

US$180m

Mar 31 2023n/an/a

US$176m

Dec 31 2022US$2mUS$455k

US$172m

Sep 30 2022n/an/a

US$154m

Jun 30 2022n/an/a

-US$106m

Mar 31 2022n/an/a

-US$101m

Dec 31 2021US$2mUS$433k

-US$173m

Sep 30 2021n/an/a

-US$145m

Jun 30 2021n/an/a

-US$138m

Mar 31 2021n/an/a

-US$131m

Dec 31 2020US$960kUS$420k

-US$44m

Sep 30 2020n/an/a

-US$35m

Jun 30 2020n/an/a

-US$98m

Mar 31 2020n/an/a

-US$105m

Dec 31 2019US$1mUS$292k

-US$113m

Compensation vs Market: Mike's total compensation ($USD1.67M) is above average for companies of similar size in the US market ($USD661.05K).

Compensation vs Earnings: Mike's compensation has been consistent with company performance over the past year.


CEO

Mike Andriole (50 yo)

less than a year

Tenure

US$1,672,620

Compensation

Mr. Michael T. Andriole, also known as Mike, is CEO, President & Director of Chimerix, Inc. since August 01, 2023 and had been the Chief Business Officer of Chimerix, Inc. since April 8, 2019 until August...


Leadership Team

NamePositionTenureCompensationOwnership
Michael Andriole
CEO, President & Directorless than a yearUS$1.67m0.35%
$ 314.1k
Allen Melemed
Chief Medical Officer3.8yrsUS$1.47m0.044%
$ 39.0k
Michelle LaSpaluto
Chief Financial Officerless than a yearno data0.12%
$ 111.0k
Thomas Riga
Chief Operating & Commercial Officerless than a yearno datano data
David Jakeman
VP of Accounting & Finance4.8yrsno data0.12%
$ 109.9k
Joshua Allen
Chief Technology Officer3.2yrsno datano data
Michael Alrutz
Senior VP9.5yrsUS$1.17m0.15%
$ 130.1k
Roy Ware
Chief Manufacturing Technology Officerless than a yearno datano data
Pablo Lee
Head of Medical Affairs1.2yrsno datano data

1.2yrs

Average Tenure

49yo

Average Age

Experienced Management: CMRX's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Michael Andriole
CEO, President & Directorless than a yearUS$1.67m0.35%
$ 314.1k
Fred Middleton
Independent Director6yrsUS$122.28k0.34%
$ 307.5k
Seth Rudnick
Member of Scientific Advisory Boardno datano datano data
Martha Demski
Lead Independent Director19.2yrsUS$147.28k0.081%
$ 72.0k
Michael Sherman
Chairman4.9yrsUS$4.06m0.37%
$ 330.4k
Douglas Richman
Member of Scientific Advisory Boardno datano datano data
Pratik Multani
Independent Director4.1yrsUS$107.28k0%
$ 0
C. Machado
Independent Director9.8yrsUS$127.28k0.011%
$ 10.0k
Michael Boeckh
Member of Clinical Advisory Boardno datano datano data
Earl Kern
Member of Scientific Advisory Boardno datano datano data
Raymund Razonable
Member of Clinical Advisory Boardno datano datano data
Robert Meyer
Independent Director6yrsUS$119.78k0.039%
$ 35.1k

6.0yrs

Average Tenure

61.5yo

Average Age

Experienced Board: CMRX's board of directors are considered experienced (6 years average tenure).


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.